Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
- 15 February 2014
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 32 (3) , 542-548
Abstract
Purpose To determine the effectiveness of bortezomib plus irinotecan and bortezomib alone in patients with advanced gastroesophageal junction (GEJ) and gastric adenocarcinoma. We also sought to explore the effect of these therapeutics on tumor and normal gene expression in vivo. Methods Forty-one patients with advanced GEJ (89 %) or gastric (11 %) adenocarcinoma received bortezomib (1.3 mg/m2 days 1, 4, 8, 11) plus irinotecan (125 mg/m2 days 1, 8) every 21 days as first line therapy (N = 29), or bortezomib alone as second line therapy (N = 12). The trial was designed to detect a 40 % response rate for the combination, and 20 % response rate for bortezomib alone. Affymetrix HU133A gene chip arrays were used for gene expression studies. Results Objective response occurred in 3 of 29 patients (10 %, 95 % confidence intervals [CI] 2 %, 27 %) treated with bortezomib plus irinotecan, and in 1 of 12 patients (8 %, 95 % CI 0 %, 39 %) with bortezomib alone. Due to the limited number of responders, there were no significant correlations with response found in the gene expression profiles of 12 patients whose tumors were sampled before and 24 h after therapy with bortezomib alone (N = 2) or the combination (N = 10). Conclusions We conclude that bortezomib is not effective for the treatment of advanced adenocarcinoma of the GEJ or stomach, whether used alone or in combination with irinotecan, in an unselected patient population.Keywords
This publication has 18 references indexed in Scilit:
- Cancer research in the global villageThe Lancet, 2010
- A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinomaInvestigational New Drugs, 2010
- Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II StudyJournal of Clinical Oncology, 2008
- Narrative Review: Protein Degradation and Human Diseases: The Ubiquitin ConnectionAnnals of Internal Medicine, 2006
- Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignanciesCancer, 2005
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancerJournal of Cellular Biochemistry, 2001
- Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.2001
- The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000